Melinta Therapeutics, LLC (Melinta), a company specializing in innovative therapies for acute and life-threatening illnesses, has joined forces with the Biomedical Advanced Research and Development Authority (BARDA) to advance two FDA-approved antibiotics, BAXDELA® and VABOMERE®, for pediatric use. Additionally, the partnership includes the development of BAXDELA® against biothreat pathogens. BARDA has provided $20.5M for the initial phase of this contract, with the potential for additional funding up to $121.4M, resulting in a total of $141.9M if all options are exercised.
The collaboration between Melinta and BARDA aims to integrate BAXDELA® and VABOMERE® into national preparedness efforts and enhance pediatric care for multi-drug-resistant bacterial infections. The ultimate goal is to increase access to these products and improve familiarity among end-users, ultimately benefiting the pediatric population in the United States.
Christine Miller, President and CEO of Melinta Therapeutics, expressed her enthusiasm about this partnership and its potential impact on patient care. She emphasized that Melinta is